Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment

Journal of Immunology

Volumn 183, Issue 11, 2009, Pages 6939-6947

  Barber, Amorette ^a   Rynda, Agnieszka ^a   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NATURAL KILLER CELL RECEPTOR NKG2D; NITRIC OXIDE; PERFORIN; TRANSCRIPTION FACTOR FOXP3; CYTOKINE; KLRK1 PROTEIN, MOUSE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADOPTIVE TRANSFER; ANIMAL; ANTIGEN PRESENTING CELL; CHIMERA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SECRETION; T LYMPHOCYTE SUBPOPULATION; TUMOR ESCAPE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; CHIMERA; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OVARIAN NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 73349123470     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902000     Document Type: Article

References (47)

1. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
2. Cohen, J. I., C. M. Bollard, R. Khanna, and S. Pittaluga. 2008. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk. Lymphoma 49(Suppl. 1): 27-34.
3. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117: 1466-1476. (Pubitemid 46871329)
4. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12: 6106-6115.
5. Nelson, B. H. 2008. The impact of T-cell immunity on ovarian cancer outcomes. Immunol. Rev. 222: 101-116. (Pubitemid 351430376)
6. Coukos, G., J. R. Conejo-Garcia, R. Buckanovich, and F. Benencia. 2007. Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv. Exp. Med. Biol. 590: 185-193.
7. Barnett, B. G., J. Ruter, I. Kryczek, M. J. Brumlik, P. J. Cheng, B. J. Daniel, G. Coukos, W. Zou, and T. J. Curiel. 2008. Regulatory T cells: a new frontier in cancer immunotherapy. Adv. Exp. Med. Biol. 622: 255-260.
8. Zou, W., and L. Chen. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8: 467-477. (Pubitemid 351733418)
9. Marigo, I., L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte. 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222: 162-179. (Pubitemid 351430364)
10. Sica, A., P. Larghi, A. Mancino, L. Rubino, C. Porta, M. G. Totaro, M. Rimoldi, S. K. Biswas, P. Allavena, and A. Mantovani. 2008. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18: 349-355.
11. Marth, C., G. H. Windbichler, H. Hausmaninger, E. Petru, K. Estermann, A. Pelzer, and E. Mueller-Holzner. 2006. Interferon-γ in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 16: 1522-1528.
12. Pujade-Lauraine, E., J. P. Guastalla, N. Colombo, P. Devillier, E. Francois, P. Fumoleau, A. Monnier, M. Nooy, L. Mignot, R. Bugat, et al. 1996. Intraperitoneal recombinant interferon γ in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. 14: 343-350.
13. Baur, M., E. Schernhammer, M. Gneist, P. Sevelda, P. Speiser, M. Hudec, and C. Dittrich. 2005. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. Br. J. Cancer 92: 1019-1025. (Pubitemid 40546663)
14. Kurbacher, C. M., J. A. Kurbacher, E. M. Cramer, K. Rhiem, P. K. Mallman, R. Reichelt, U. Reinhold, U. Stier, and I. A. Cree. 2005. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Williston Park). 19: 23-26.
15. Barnett, B., I. Kryczek, P. Cheng, W. Zou, and T. J. Curiel. 2005. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 54: 369-377. (Pubitemid 41748714)
16. Hodi, F. S., M. Butler, D. A. Oble, M. V. Seiden, F. G. Haluska, A. Kruse, S. Macrae, M. Nelson, C. Canning, I. Lowy, et al. 2008. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 105: 3005-3010.
17. Barber, A., T. Zhang, and C. L. Sentman. 2008. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J. Immunol. 180: 72-78.
18. Zhang, T., A. Barber, and C. L. Sentman. 2007. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 67: 11029-11036. (Pubitemid 350145933)
19. Barber, A., T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman. 2007. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67: 5003-5008. (Pubitemid 46910210)
20. Zhang, T., A. Barber, and C. L. Sentman. 2006. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66: 5927-5933. (Pubitemid 43927148)
21. Zhang, T., B. A. Lemoi, and C. L. Sentman. 2005. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551. (Pubitemid 41208564)
22. + myeloid cells. Cancer Res. 66: 6807-6815.
23. Geissmann, F., C. Auffray, R. Palframan, C. Wirrig, A. Ciocca, L. Campisi, E. Narni-Mancinelli, and G. Lauvau. 2008. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol. Cell Biol. 86: 398-408. (Pubitemid 351948210)
24. Liu, Y., B. Zeng, Z. Zhang, Y. Zhang, and R. Yang. 2008. B7-H1 on myeloidderived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin. Immunol. 129: 471-481.
25. Kryczek, I., S. Wei, G. Zhu, L. Myers, P. Mottram, P. Cheng, L. Chen, G. Coukos, and W. Zou. 2007. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67: 8900-8905. (Pubitemid 47437467)
26. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 104: 3360-3365.
27. Curiel, T. J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. L. Knutson, B. Daniel, M. C. Zimmermann, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9: 562-567.
28. Bak, S. P., A. Alonso, M. J. Turk, and B. Berwin. 2008. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol. Immunol. 46: 258-268.
29. +-activated macrophages induced during acute toxoplasmosis. J. Leukocyte Biol. 74: 1015-1025.
30. + monocytes is essential for control of acute toxoplasmosis. J. Exp. Med. 201: 1761-1769.
31. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
32. Wolf, D., A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, G. Gastl, E. Gunsilius, and C. Marth. 2005. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11: 8326-8331. (Pubitemid 41746944)
33. Roy, S., P. F. Barnes, A. Garg, S. Wu, D. Cosman, and R. Vankayalapati. 2008. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J. Immunol. 180: 1729-1736.
34. Zhong, X., J. R. Tumang, W. Gao, C. Bai, and T. L. Rothstein. 2007. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur. J. Immunol. 37: 2405-2410. (Pubitemid 47423611)
35. Bouaziz, J. D., K. Yanaba, and T. F. Tedder. 2008. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224: 201-214.
36. Ha, S. A., M. Tsuji, K. Suzuki, B. Meek, N. Yasuda, T. Kaisho, and S. Fagarasan. 2006. Regulation of B1 cell migration by signals through Toll-like receptors. J. Exp. Med. 203: 2541-2550.
37. Balabanian, K., A. Foussat, L. Bouchet-Delbos, J. Couderc, R. Krzysiek, A. Amara, F. Baleux, A. Portier, P. Galanaud, and D. Emilie. 2002. Interleukin-10 modulates the sensitivity of peritoneal B lymphocytes to chemokines with opposite effects on stromal cell-derived factor-1 and B-lymphocyte chemoattractant. Blood 99: 427-436.
38. Miyake, K. 2007. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 19: 3-10. (Pubitemid 46498750)
39. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukocyte Biol. 75: 163-189. (Pubitemid 38174573)
40. Dunn, G. P., C. M. Koebel, and R. D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6: 836-848.
41. Blankenstein, T., and Z. Qin. 2003. The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol. 15: 148-154. (Pubitemid 36287519)
42. Marth, C., H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, W. Doppler, and G. Daxenbichler. 2004. Interferon-γ expression is an independent prognostic factor in ovarian cancer. Am. J. Obstet. Gynecol. 191: 1598-1605.
43. Kusuda, T., K. Shigemasa, K. Arihiro, T. Fujii, N. Nagai, and K. Ohama. 2005. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol. Rep. 13: 1153-1158.
44. Barber, A., and C. L. Sentman. 2009. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J. Immunol. 183: 2365-2372.
45. Mocellin, S., V. Bronte, and D. Nitti. 2007. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med. Res. Rev. 27: 317-352.
46. Huerta, S., S. Chilka, and B. Bonavida. 2008. Nitric oxide donors: novel cancer therapeutics (review). Int. J. Oncol. 33: 909-927.
47. Hagemann, T., T. Lawrence, I. McNeish, K. A. Charles, H. Kulbe, R. G. Thompson, S. C. Robinson, and F. R. Balkwill. 2008. "Re-educating" tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 205: 1261-1268.